/Antu Biotechnology 2025 Social Responsibility Report

NEWS

Antu Biotechnology 2025 Social Responsibility Report

Shanghai Stock Exchange

2026/04/23

2 0 2 5

Antu Bio Social Responsibility Report

Committed to the popularization and improvement of medical laboratory technology to serve human health. Report preparation instructions

The social responsibility report of Zhengzhou Antu Bioengineering Co., Ltd. (referred to as "Antu Bio" and the "Company"), based on the principles of objectivity and standardization, comprehensively discloses the company's work and achievements in corporate governance, corporate high-quality and sustainable development, protection of the rights and interests of shareholders and employees, and social responsibility.

Reporting scope

This report is the 2025 annual report, covering relevant data from January 1, 2025 to December 31, 2025, and also involves relevant situations since the establishment of the company. The coverage of this report includes Antu Biotech and its subsidiaries.

Compilation basis

Shanghai Stock Exchange "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operations".

Report Description

Antu Biotech guarantees that this report does not contain any false records and misleading statements, and that the data is consistent with the same indicators disclosed in the "2025 Annual Report of Zhengzhou Antu Bioengineering Co., Ltd."

How to get it

This report is released in both paper and electronic formats. You can read it on the information disclosure website designated by the Shanghai Stock Exchange or log in to the company's website.

Antu Biotechnology 2025 Social Responsibility Report

CONTENTS

Directory

Overview Employee Responsibilities

Gather momentum and forge ahead, innovate and expand, lead with strength, and write a new chapter 01 Talent Strategy 28 Career Development 30

Occupational Safety 33 Key Performance

Employee protection 36

green development

Company Profile

Green Management 40 Company Profile 06 Green Building 41 Review of Major Events in 2025 07 Green Logistics 41 Corporate Culture 09 Green Office 41 Corporate Strategy 10 Energy Saving and Low Carbon 41 Party Building Work 11 Pollutant Management 42 Qualifications and Honors 12 Compliance and Environmental Protection Investment 44

02 06Corporate Governance Social Responsibility

Adhere to standardized operations and continue to improve governance levels 14 Help cultivate inspection talents,

Establish "Antu Advance Scholarship" 46 Pay attention to the interests of investors and implement investor returns 15

Support the army and provide good care,

High-quality compliance disclosure and emphasis on investment and customs management 16

Establish "Antu Advance Veterans Solace Fund" 46 Strict internal control management and optimize the construction of internal control system 18

03 07High quality development and future prospects

Innovation leads the high-quality development of enterprises 20 Innovation empowers to improve quality and efficiency, and deepens industry to build health 48 Pursue excellent manufacturing and create high-quality products 22

Diversified services create value 26

Overview

Gather momentum and forge ahead, innovate and expand, lead with strength, and write a new chapter

The year 2025 is a year of deep adjustments, challenges and opportunities for the in vitro diagnostic industry. In the field of home testing, the company launched three respiratory antigen detection kits. "AI+ testing" is reshaping the boundaries of the industry, and home testing consumers are gradually awakening. Among them, adenovirus and respiratory syncytial virus antigen detection kits have become the first in the country. Internet platforms are accelerating the penetration of testing scenarios. The in vitro diagnostic industry is experiencing profound technological iterations and restructuring of the market. Approved consumer self-testing reagents have filled the market gap in the field of home self-testing. At the same time, the domestic macroeconomic situation declined. In addition, the microbial BC120 Plus blood culture instrument was successfully launched. Fluctuations in the lower respiratory tract and medical industry policy reforms brought dual pressures. Centralized procurement comprehensively launched 4 products with 12 targets simultaneously, further enriching the implementation of accurate detection products, deepening of DRG/DIP payment reform, promotion of unbundling of test packages, and test product matrix.

The "new normal" of the industry such as mutual recognition of results has a positive impact on the operational resilience of in vitro diagnostic companies

Bravely shoulder heavy responsibilities and actively undertake major scientific research projects

constitutes a comprehensive test.

In 2025, Antu Biotech will actively undertake major national scientific research projects and rely on industry and academia to face changes and challenges. Antu people will work together to break through the situation and move forward with innovation.

Research integration platform accelerates the transformation of scientific research results, helps break through key technologies in the industry, and uses collaborative efforts to stabilize the development trend in a complex environment.

Bottlenecks, improving the overall technical level of my country's in vitro diagnostic industry and international competition and breakthroughs have written the 2025 answer sheet belonging to Antu Biotech.

competitiveness.

Break through innovation and promote comprehensive product research and development

Antu Biotech deeply promotes the collaborative innovation of industry, academia and research, and cooperates with the First Affiliated Hospital of Xi'an Jiaotong University in terms of product strategy. Antu Biotech always regards innovation as the core of development and launches the "Tumor Molecular Diagnostic Technology Research and Development and Clinical Application" project. Focusing on the engine, it continues to increase investment in R&D, promotes positional and comprehensive product research and development, and solves early tumor screening and diagnosis and treatment problems. It relies on the establishment of intelligent testing research institutes to continuously consolidate its advantages in core areas, fill technological gaps, and expand product boundaries. to accelerate the implementation of "laboratory to bedside" technology; and held a promotion meeting for "Yalin uses a rich product line to meet clinical multi-level and diversified needs for cross-clinical primary aldosteronism cohort research" to lay a solid foundation for the project direction and the national industry cycle. By the end of 2025, the company's total number of medical device registration certificates (prepared to the National Health Commission's "Recommended Guidelines for Adult Health Examination Items (2025 Edition)") certificates exceeded 1,000, with 204 new ones added annually. The rich product menu is suitable for promoting early screening of formaldehyde into a new stage of policy support. At the same time, participating orders provide the market with more choices. "Prevalence of Hepatitis E in Special Populations" led by Peking University Health Science Center

Research, through national multi-center design, mapped the HEV of my country's special population for the first time on the core track. The company's magnetic particle chemiluminescence technology continues to lead the immune system.

The panoramic map of infection provides strong support for hepatitis prevention and control. The antigen and antibody self-sufficiency rate of diagnostic reagent products is high, ensuring a stable supply of products.

Qualitativeness and safety. At present, the company has 22 major categories and 223 related products. In terms of promoting major national projects, Antu Biotech has undertaken two products from the Ministry of Industry and Information Technology, ranking first in the industry. For different application scenarios, the company has launched the industry chain main project; the company-led "Automated clinical testing laboratory promotes AutoLumo S900 series products and continues the mature magnetic particle chemiluminescence technology application project" announced by the Ministry of Industry and Information Technology and other three ministries and commissions as the "2025 high-end medical device technology platform, which is compact and efficient, energy-saving and intelligent, and easy to operate. It is precise and In the "Preparation Promotion and Application Project", it ranks first in the IVD automated clinical laboratory category and accurately meets the needs of emergency departments, compact laboratories, grassroots departments and other scenarios. First, it demonstrates Antu Biotech’s strong strength in the field of high-end medical equipment. In terms of technological breakthroughs, the company's wholly-owned subsidiary Sikun Biotech has deepened cooperation to build a new ecosystem for global cooperation.

Three gene sequencers, 2000, Sikun 1000 and Sikun 500, were successfully certified.

Antu Biotech continues to deepen its international cooperation and build a new ecosystem for global cooperation. Core components and reagent raw materials have been independently developed, successfully filling the relevant

Joining hands with Malaysian Interscience Sdn Bhd and Premier Integrat - technology gap.

Antu Biotechnology 2025 Social Responsibility Report

ed Lab, promotes the introduction of microbial mass spectrometry products in Southeast Asia; subsidiary Shanghai Standard's R&D investment and stable operating income are once again on the list; it topped the 2025 "China Source cooperates with Malaysian McQAS to improve regional laboratory quality control levels; IVD Enterprise R&D Strength Ranking", demonstrating strong innovation and solid strength through the Biominds Talk academic conference, and international clinical chemistry and laboratory medicine; fully automatic biochemical analyzer AutoChem The B2000 series won the German iF Federation (IFCC) jointly organized seminars and other forms, inviting internationally renowned experts to design awards; the assembly line Autolas X-1 won the 25th China Patent Award, sharing cutting-edge experience, and building a cross-border technology exchange bridge. The Design Excellence Award reflects the company's dual breakthroughs in product design and technological innovation. In addition, the company also won the "National" Award from the All-China Federation of Trade Unions. Facing higher thresholds in the European and American markets, the company first adopted technical certification pre-positioning

The title of "Model Employee Home" has witnessed the company's care for the growth of its employees and its condensed strategies. It has obtained 383 EU CE IVDR registration certificates, including infectious diseases.

Gather the firm belief of common development between employees and the enterprise.

4 IVDR CE Class D certifications in the field, technical strength in line with the highest international standards

Accurate, laying the foundation for entering the European high-end market. Although it is hard work to search for thousands of pounds, you will only get gold after blowing all the sand. Looking back on 2025, Antu Biotech faced challenges during the industry adjustment period, transformed external pressure into endogenous power, won multiple awards, and was widely recognized by society and the industry.

Solid progress has been made in product innovation, scientific research, and global expansion. In 2025, Antu Biotech will rely on its outstanding innovation strength, industry influence and social

Exhibition. These achievements are inseparable from the perseverance, wisdom and contribution of every Antu person. They have won many honors and have been widely recognized by the country, industry and all walks of life.

and sweat, but also inseparable from the trust and support from all walks of life. Antu Biotechnology will be recognized by all, and every honor is the best affirmation of the company’s persistence and innovation.

Stay true to our original aspiration, use innovation as the engine, continue to deepen the integration of industry, academia and research, and further expansion will inspire future development.

Expand global cooperation territory, actively assume social responsibilities, continue to promote the company's high-quality Antu Biotech to be selected into the list of "Top 100 Enterprises in China's Pharmaceutical Industry", develop with solid quantity, and write a more brilliant development chapter.

Aerial view of Antu Bio-In vitro Diagnostics Industrial Park

key performance

operating results

In 2025, the company will achieve operating income of 4.226 billion yuan, a year-on-year decrease of 5.47%; in 2025, the company will invest 10.768 million yuan in environmental protection. Net profit attributable to shareholders of listed companies was 1.068 billion yuan, a year-on-year decrease of 10.59%.

As of the end of 2025, the company has a total of 5,700 employees and R&D investment of

Among them, there are 2,005 R&D personnel, accounting for 35.18%;

There are 4,150 people with bachelor's degree or above, accounting for 72.81%. In 2025, the company invested 768 million yuan in research and development, accounting for 18.16% of that year's operating income.

Antu Biotechnology 2025 Social Responsibility Report

Operating performance Environmental protection investment

Staff situation

As of the end of 2025, the company has a total of 5,700 employees, including 2,005 R&D personnel, accounting for 35.18%;

Committed to the popularization and improvement of medical laboratory technology to serve human health.

Antu Biotechnology 2025 Social Responsibility Report

Company Profile

Zhengzhou Antu Bioengineering Co., Ltd. (referred to as "Antu Bio") is a shareholder of major provincial and municipal science and technology projects and has fully participated in 116 national/industry standards.

(ticket code 603658) was founded in 1998 and is headquartered in Zhengzhou Economic and Technical Development.

development zone.

Antu Bio’s marketing network covers the whole country, and its products have been sold to more than 10,000 medical machines.

Antu Biotechnology focuses on the research and development, manufacturing, and integration of in vitro diagnostic reagents and instruments. In terms of international marketing, the company's products have been sold to Europe, Asia, China and

And services, the products cover immunity, microbiology, biochemistry, molecules, coagulation and other testing areas in East, South America, Africa and other regions.

testing field, and extends to sequencing, mass spectrometry, quality control products, and smart medical experiments

Antu Biological In Vitro Diagnostic Industrial Park has a construction area of 251 acres, with a construction area of 100,000 square meters and a compact medical consortium construction. It can provide comprehensive services for medical laboratories.

With an area of more than 720,000 square meters, it mainly houses an in vitro diagnostic reagent and instrument R&D center, comprehensive product solutions and overall services. The company was listed on September 1, 2016

It has a modern manufacturing center, a large three-dimensional refrigerated finished product warehouse, and China's first in-vitro diagnostic R&D company listed on the main board of the Shanghai Stock Exchange.

Museum of Laboratory Medicine, etc., once fully completed, it will become the largest in vitro diagnostic and manufacturing enterprise in China.

One of the industrial bases.

Antu Biotechnology was approved by the National Development and Reform Commission to lead the formation of a new major

Antu Biotech adheres to the principle of "committed to the popularization and improvement of medical laboratory technology. It is a national engineering research center for infectious disease detection, has a national enterprise technology center, and a free

With the purpose of "Human Health Services", innovation drives the high-quality development of enterprises, and the National and Local Joint Engineering Laboratory for Epidemic Detection Automation and Henan Provincial Immunological Diagnostics

Strive to build an in vitro diagnostic enterprise that deeply integrates advanced manufacturing and high-end services. Reagent Engineering Technology Research Center, Henan Mass Spectrometry Technology Innovation Center, Henan

Provincial in vitro diagnostic product pilot base and other innovation platforms; undertook dozens of national

Review of major events in 2025

January 2025

The 1,000th piece of equipment of the Autof ms series of Antu Bio's microbial mass spectrometers has officially rolled off the production line. At the same time, a new generation of microbial mass spectrometry detection systems, the Autof T series, has been launched. This marks that Antu Bio's continuous innovation and industrialization capabilities in the field of microbial mass spectrometry have reached a new level.

March 2025

Antu Biotech and the First Affiliated Hospital of Xi'an Jiaotong University jointly launched the "Tumor Molecular Diagnostic Technology Research and Development and Clinical Application" project, focusing on early screening and diagnosis and treatment problems, relying on the Intelligent Laboratory Research Institute to build a transformation platform to accelerate the transformation of "laboratory to bedside" results.

May 2025

Antu Biotechnology launches the AutoLumo S900 series of products, continuing the mature magnetic particle chemiluminescence technology platform. It is compact, efficient, energy-saving, intelligent, and easy to operate, and accurately matches the needs of emergency departments, compact laboratories, grassroots departments and other scenarios.

June 2025

Antu Biotech and MaxSide have reached a strategic cooperation to achieve technology, product and market synergy in the field of urine analysis, promote the intelligent upgrading of the industry, and provide more accurate solutions for clinical laboratories.

July 2025

Antu Biotech and Jiuzhoutong Pharmaceutical Group have reached a strategic cooperation to expand channels and markets through resource sharing, and work together to develop markets so that high-quality products and services can reach more customers.

Antu Biotechnology 2025 Social Responsibility Report

October 2025

Antu Biotech has launched three respiratory antigen detection kits. Among them, the adenovirus and respiratory syncytial virus antigen detection kits have become the first approved consumer self-testing kits in China, filling the gap in the field of home self-testing.

November 2025

The number of Antu Biomagnetic Particle Chemiluminescence products has reached 223, ranking first in the industry in terms of product number, and has formed a complete testing system covering 22 categories. This milestone breakthrough not only marks Antu Biotech's continued leadership in the field of immunoassays, but also represents an important leap forward in the core technology field of in vitro diagnostics, chemiluminescence detection.

December 2025

The "Automated Clinical Testing Laboratory Promotion and Application Project" led by Antu Biotechnology ranked first in the IVD automated clinical laboratory category in the "2025 High-end Medical Equipment Promotion and Application Project" announced by the Ministry of Industry and Information Technology and other three ministries, demonstrating the company's strong strength in the field of high-end medical equipment.

December 2025

Sikun Bio, a wholly-owned subsidiary of Antu Bio, has obtained certification for its three gene sequencers, Sikun 2000, Sikun 1000, and Sikun 500. The core components and reagent raw materials have been independently developed, successfully filling the relevant technical gaps.

December 2025

The total number of Antu Biomedical Device Registration (Filing) Certificates exceeded 1,000, and 204 new medical device registration (Filing) Certificates were added.

corporate culture

Antu Biotechnology attaches great importance to the construction of corporate culture. In the course of more than 20 years of development, all Antu people have practiced the original intention of "serving human health" within the direction indicated by the corporate purpose, constantly refined and summarized, and formed a unique corporate culture system that keeps pace with the times. Antu Bio's corporate culture is not only the code of conduct for Antu's people, but also provides important support for Antu's strategy, operation, and management.

Corporate philosophy

Business philosophy

We will do our best to provide users with products and services with better performance-price ratio and quality-price ratio.

Quality concept

Quality is the life of an enterprise and the fundamental basis of its brand power;

From R&D, production, sales to service, quality attention and participation of all members in the entire process;

Pursue excellence, strive for excellence, high standards, strict requirements, and continuous optimization and improvement.

eight

Customer first, market-oriented

Great employment concept

Price People-oriented, focus on personal development

Employ people based on their strengths; people first, policy second;

value

Pursue excellence and strictly implement optimization and innovation

Observation Quality requirements for managers: team awareness, courage to take responsibility; passion, good decision-making, love for the team, and emphasis on self-contribution

Policy and execution ability.

Strengthen communication and be honest

Take responsibility bravely and reject blame-shifting. Team concept

Follow orders and strictly abide by rules and regulations. Talents and teams are the core competitiveness of an enterprise. We must build a learning team that is united, treated differently, strict in performance appraisal, striving, realistic and honest.

Antu Biotechnology 2025 Social Responsibility Report

corporate strategy

An enterprise's strategy is the bridge between the organization's current situation and its future goals. Based on the corporate mission, vision and values, Antu Biotech adheres to the concept of innovative development, firmly grasps the important strategic opportunities of the country's deepening of economic structural adjustment and industrial transformation and upgrading, and combines the industry and its own development trends to scientifically formulate corporate strategic goals, clarify long-term and short-term development tasks, and support the company's sustainable and healthy development.

Product and service strategy

Focus on the field of medical laboratories and provide users with comprehensive product and service solutions.

competitive strategy

Pursue excellence and never stop innovating, optimizing and improving all work, mainly research and development work;

We have long-term and tenacious accumulation of small advantages in all aspects to provide users with products and services with better performance-price ratio and quality-price ratio.

Eight values

medium to long term strategy

Upgrade from traditional advantage areas to emerging and leading project areas;

Upgrading from the field of traditional diagnosis to the field of precision diagnosis;

Upgrade from a pure advanced manufacturing enterprise to an in vitro diagnostic enterprise that deeply integrates advanced manufacturing and high-end services.

Party building work

In 2025, the Fourth Plenary Session of the 20th Central Committee of the Communist Party of China made clear arrangements for persistently promoting comprehensive and strict party governance, emphasizing that the party's self-revolution should lead the social revolution and provide fundamental guarantees for Chinese-style modernization to comprehensively promote the construction of a strong country and the great cause of national rejuvenation. The high-quality development of private enterprises cannot be separated from the party's innovative theoretical guidance, the policy support of the party and the state, and the strong leadership of grassroots party organizations.

Antu Biotechnology has always attached great importance to party building work. As one of the earliest private enterprises in Zhengzhou to establish a party branch, since the establishment of the party committee in 2007, it has always insisted on using party building to lead the high-quality development of the company. In 2025, Antu Biology Party Committee will further consolidate the foundation of party building and deepen the integration of party building and business. All party members show their identity and set an example in each position, give full play to the vanguard and exemplary role of party members, and serve as both the "vanguard" of the company's development and the "connecting bridge" between the party and the masses, gathering forge ahead for the development of the company. Combining the company's national business layout and innovating the organizational coverage model, 28 party groups have been set up in various provinces and cities across the country to achieve "where the business expands, the party organization will cover it, and the party work will be followed up", which has become a distinctive feature of Antu Bio's party building work. It has comprehensively improved the leadership, cohesion and combat effectiveness of grassroots party organizations, promoted the in-depth integration of party building work with technological innovation, market expansion and other business work, and effectively promoted the steady development of the company.

In 2025, Antu Biological Party Committee will closely follow the annual party building work focus, take normalized organizational life as the starting point, solidly promote grassroots party building to improve quality and efficiency, organize party members to carry out various forms of learning, education and practical activities, and promote party building work to be in-depth and practical. First, strengthen theoretical arming and organizational building, strictly implement the Party Central Committee’s deployment, organize party members to study in-depth classic works such as "Selected Readings of Xi Jinping's Works" and "Xi Jinping: The Governance of China", study the party's important historical documents and resolutions, and build a solid ideological foundation; two enlarged party committee meetings were held throughout the year to deploy special arrangements for evaluation, key party building work and annual summary planning, and held an advanced commendation and all party members conference to gather the forge ahead of "compare learning and catch up". The second is to deepen red education, inherit the red gene, organize party members to go to the Guangshan County Party School to carry out red training, combine the spirit of the Fourth Plenary Session of the 20th Central Committee of the Party, deeply cultivate the spirit of the Dabie Mountains, review the original aspiration and mission, and strengthen ideals and beliefs; continue to carry out activities to care for revolutionary veterans, organize party member representatives to visit Nanzhao County to visit poor veterans, and inherit the revolutionary spirit. The third is to promote the deep integration of party building and innovation. The party committee took the lead in establishing the "Party Member Innovation Pioneer Post" and "Party Member Technical Research Group" to organize key members of the party to focus on technical problems in the industry and clinical testing needs.

Antu Biology Party Committee will adhere to the guidance of the party's innovation theory, thoroughly implement the deployment requirements of superior party organizations, focus on the key points of party building work in emerging fields, deepen the integration of party building and business, innovate party building work methods and methods, enrich the form of mass activities for party members, promote the quality and efficiency of party building work with higher standards and more practical measures, and contribute to the high-quality development of the enterprise.

Antu Biotechnology 2025 Social Responsibility Report

Qualifications and Honors Won the honorary title of “National Model Workers’ Home” awarded by the All-China Federation of Trade Unions. Won the honorary title of "Henan Province Innovation Leading Enterprise".

Once again ranked among the "Top 100 Enterprises in China's Pharmaceutical Industry".

Won the title of "Top Ten High-Growth Technology Leading Enterprises in Henan Province".

Won the honorary title of "Honesty and Trustworthy Model Enterprise" issued by Zhengzhou Medical Device Industry Association. Won the first prize of the "2025 Zhengzhou High-Value Patent Operation Competition".

Antu Biotech has always strictly complied with the requirements of the Company Law, Securities Law, Code of Governance of Listed Companies, Shanghai Stock Exchange Stock Listing Rules, and relevant laws, regulations and normative documents issued by the China Securities Regulatory Commission and other relevant departments, constantly improving the corporate governance structure, establishing and improving the internal management and control system, standardizing the company's operations, continuously improving the company's competitiveness, and repaying shareholders and society with better operating performance.

Antu Biotechnology 2025 Social Responsibility Report

Adhere to standardized operations and continue to improve governance levels

According to the "Company Law of the People's Republic of China" and the "Company Law of the People's Republic of China"

Securities Law and other relevant laws and regulations and the requirements of the Articles of Association to construct

The shareholders’ meeting, the board of directors, the special committees of the board of directors and the operating management

The corporate governance system composed of others has formed a power agency, decision-making agency,

Supervisory agencies and executive agencies cooperate, coordinate and control each other.

maintain a balanced operating mechanism to promote the company’s standardized operations and effectively protect the company and

the legitimate rights and interests of shareholders.

The company's shareholders' meeting is composed of all shareholders of the company and is the company's highest authority. The company strictly complies with the provisions and requirements of the "Rules for Shareholders' Meetings of Listed Companies", "Articles of Association" and "Rules of Procedure for Shareholders' Meetings" to standardize the holding of shareholders' meetings and ensure that shareholders can exercise their rights and interests equally.

rights and safeguard the legitimate rights and interests of all shareholders, especially small and medium shareholders.

shareholders meeting

During the reporting period, the company held a total of 3 shareholders' meetings and reviewed 13 proposals.

The board of directors is the company's daily decision-making body and is accountable to the shareholders' meeting. It consists of four special committees: the audit committee, the strategic development committee, the remuneration and assessment committee, and the nomination committee. The company currently has 12 directors on the fifth session of the board of directors, including 4 independent directors and 1 employee representative director. The composition of the board of directors complies with the requirements of laws, regulations and the Articles of Association. Directors of the company's board of directors and

In accordance with the relevant provisions of the "Articles of Association", "Rules of Procedure of the Board of Directors" and the implementation rules of each special committee, we shall perform our duties diligently and in compliance with the requirements of the Board of Directors.

Carry out all work in a regular and efficient manner.

During the reporting period, the company held a total of 7 board meetings and reviewed 33 proposals.

The company's controlling shareholders strictly regulate their behavior in accordance with the "Code of Corporate Governance for Listed Companies", "Shanghai Stock Exchange Stock Listing Rules", "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operations", "Articles of Association" and other regulations and requirements. There is no behavior that directly or indirectly interferes with the company's decision-making and operating activities beyond the company's shareholders' meeting; no behavior has harmed the company and other shareholders. Controlling shareholders

interests, the controlling shareholder does not occupy the company's funds, and the company does not provide guarantees for the controlling shareholder. The company has independence

It has independent and complete business and independent operating capabilities. It is independent from the controlling shareholder in terms of business, personnel, assets, institutions and finance. The company's board of directors and internal institutions operate independently.

Pay attention to the interests of investors and implement high shareholder returns

The company has always maintained a high degree of respect for the rights and interests of investors and a responsible attitude, and deeply understands that creating and ensuring reasonable and stable investment returns for investors is one of the core responsibilities of the company to effectively fulfill its social responsibilities. The company has always attached great importance to shareholders' rights and investor returns. While maintaining the company's sustainable development and economic growth, it is committed to providing shareholders with stable and sustained cash dividend returns. At the same time, the company actively promotes share repurchases and increases holdings of controlling shareholders to enhance shareholder investment confidence and investment value.

While optimizing operations and improving performance, the company also attaches great importance to reasonable returns to investors. Since its listing in 2016, the company has insisted on actively rewarding investors with a high proportion of dividends so that investors can share the corporate value; it gives priority to using cash dividends to distribute profits and equity.

Match. From 2016 to 2024, the company's cumulative cash dividends totaled RMB 4.047 billion, which effectively demonstrated the company's long-term investment value.

Dividends per 10 shares per 10 shares per 10 shares Cash dividends are returned in cash Total dividend amount Annual consolidated report of dividends accounts for the year in the consolidated statement Number of dividends Number of transfers Amount of shares purchased and canceled (tax included) Number of shares attributable to listed companies in the table (yuan) (shares) (tax included) Amount included in cash dividends The company's common stock shareholders The company's common shareholders (shares) (tax included) ratio of net profit to net profit

Rate (%) 2016 0 6.50 0 273,000,000.00 0 273,000,000.00 349,758,059.57 78.05 2017 0 10.80 0 453,600,000.00 0 453,600,000.00 446,564,158.65 101.58 2018 0 8.00 0 336,000,000.00 0 336,000,000.00 562,570,893.30 59.73 2019 0 9.00 0 387,542,609.10 0 387,542,609.10 774,163,957.63 50.06 2020 0 8.50 3 383,331,860.15 0 383,331,860.15 747,793,833.41 51.26 2021 0 7.20 0 419,842,473.12 0 419,842,473.12 973,663,074.64 43.12 2022 0 8.00 0 464,809,076.80 243,300,008.68 708,109,085.48 1,167,437,129.39 60.66 2023 0 10.52 0 608,800,164.62 0 608,800,164.62 1,217,438,887.27 50.01 2024 0 12.60 0 719,995,207.68 436,359,364.05 1,156,354,571.73 1,194,451,909.72 96.81

With its steadily improving dividend plan, the company ranked 39th in the dividend payout ratio list of the China Association of Public Companies' 2025 cash dividend list of listed companies.

In 2025, the company plans to distribute cash dividends per share to all shareholders 1.31 yuan (tax included). As of April 21, 2026, the company's total share capital was 571,424,768 shares. Based on this calculation, the total cash dividend to be distributed is 748,566,446.08 yuan (tax included); the amount of cash dividends to be repurchased and canceled through centralized bidding is 9,123,256.92 yuan. Yuan (including transaction costs), the total amount of cash dividends, repurchases and cancellations was 757,689,703.00 yuan, accounting for 70.94% of the net profit attributable to shareholders of listed companies this year.

Antu Biotechnology 2025 Social Responsibility Report

In February 2024, the company further increased its repurchase efforts and effectively implemented the cancellation-type repurchase plan, aiming to increase the share repurchase rate in return of shareholders' equity, safeguard and enhance the interests of investors, and at the same time boost market confidence. As of February 19, 2025, the company has completed this cancellation and repurchase, and has actually repurchased a total of 9,586,578 shares of the company through centralized bidding transactions, accounting for 1.65% of the company's total share capital. The shares repurchased have been canceled on February 21, 2025.

Based on confidence in the company's future development prospects and recognition of the company's value, and in order to effectively protect the rights and interests of investors and enhance investor confidence, in August 2024, the company's controlling shareholder Zhengzhou Antu Industrial Group Co., Ltd. (hereinafter referred to as "Antu Industrial Group Co., Ltd."

Antu Industrial") implemented shareholding increase. As of February 20, 2025, this shareholding increase plan has been completed, and Antu Industrial increased its shareholding through concentrated competition

A total of 5,541,300 shares of the company were increased through price transactions, accounting for 0.95% of the company's total share capital. The cumulative increase in holdings was 218,943,721.67 yuan.

Item Amount (yuan)

Total social contribution in 2025 2,848,694,219.79

Employee security (wages, salaries and labor fees, benefits, wage surcharges) 1,261,091,596.93

Per share 2. Taxation (business tax and surcharges, income tax, other taxes) 487,966,552.96

social contribution value

Loan interest 13,251,847.85
Net profit (including gains and losses of minority shareholders) 1,086,384,222.05

Total share capital at the end of the period 571,424,768.00

Social contribution per share 4.99

High-quality compliance disclosure and emphasis on investment and customs management

The company strictly complies with the relevant requirements of the Securities Law, the Stock Listing Rules of the Shanghai Stock Exchange, the Management Measures for Information Disclosure of Listed Companies and other normative documents, strictly performs its information disclosure obligations, ensures that the disclosed information is true, accurate, and complete, and that the information disclosed is timely and fair. It also continuously improves the readability and effectiveness of information disclosure to facilitate investors to understand the company's operations and enhance the company's information transparency.

During the reporting period, the company released 4 regular reports and 86 temporary announcements on the Shanghai Stock Exchange platform (www.sse.com.cn).

copies and published in the designated media "Shanghai Securities News" and "Securities Times". The company strictly follows the guidelines for information disclosure formats, makes announcements accurate and clear, and resolutely refuses to speculate on hot topics. At the same time, the company takes corresponding measures in accordance with the requirements of the "Insider Information Registration and Management System for Listed Companies" to effectively prevent the leakage of inside information, ensure that all shareholders have fair and just access to company information, and effectively protect the legitimate rights and interests of investors. In view of the company's long-standing high-quality disclosure work, the Shanghai Stock Exchange issued a "Letter of Appreciation on Matters Related to Antu Bio's Information Disclosure Work" to the company, which highly affirmed the company's disclosure quality and standardized operation level.

The company attaches great importance to investor relations management. Through performance briefings, investor surveys, brokerage strategy meetings, and the Shanghai Stock Exchange e-interactive platform, it promptly communicates and responds to issues of concern to investors such as corporate governance, operating conditions, and development strategies. It conducts two-way communication with investors at multiple levels and through multiple channels, fully protects investors' right to know, and establishes a good interactive relationship between listed companies and investors. The company always keeps open communication channels such as telephone, e-mail and fax, and responds and provides feedback to investors in effective forms.

During the reporting period, the company continued to maintain a 100% response rate on the Shanghai Stock Exchange E interactive platform, held 3 regular report performance briefings on a regular basis, shortened the distance with investors through video recording and online interaction, and won the "Excellent Practice of Listed Companies' 2024 Annual Report Performance Briefing" award. At the same time, the company actively participates in various surveys organized by the Shanghai Stock Exchange and institutional investors, releases 8 investor relations activity records through the "Listed Investor Company Release Platform", and promptly announces the main content of the company's investor relations activities. Public relations management treats investors fairly and puts investors' interests in a more prominent position.

In addition, the company actively participated in the 2025 investor online collective reception day event for listed companies in Henan jurisdiction, and jointly launched the 2025 "I am a shareholder" small and medium-sized investors' visit to Shanghai-listed companies - Antu Biotech with CICC Wealth Management to enhance communication with investors, demonstrate the company's intrinsic value, and effectively protect the interests of shareholders, especially small and medium-sized shareholders.

Antu Biotechnology 2025 Social Responsibility Report

Strict internal control management and optimize the construction of internal control system

The company has always attached great importance to the system construction and implementation of internal control. Based on the framework of normative documents such as the "Basic Standards for Enterprise Internal Control" promulgated by the Ministry of Finance and the "Guidelines for Internal Control of Listed Companies" issued by the Shanghai Stock Exchange, and combined with the company's actual operating governance and corporate culture, it has established a systematic and standardized internal control system with Antu characteristics. Under this system, the company has further revised and improved the "Antu Bio Internal Control Manual" to provide guidance and basis for the establishment, operation, supervision, evaluation and maintenance of the internal control system; it has also refined and formulated the company's internal management systems such as the "Antu Bio Internal Control System", "Antu Bio Internal Audit System" and "Antu Bio Internal Control Evaluation Methods", covering all production and operation links, business departments and holding subsidiaries of the company, and continues to revise and improve them. At the same time, the company regularly conducts self-evaluations on the effectiveness of the internal control system and issues an "Internal Control Evaluation Report", and hires an audit agency to audit the company's internal controls and issue an "Internal Control Audit Report" to effectively supervise the company's standardized operations and high-quality development.

Under the leadership of the Board of Directors and the Audit Committee, the Company's Internal Audit Department independently carries out internal audit work in strict accordance with the internal audit system, evaluates the effectiveness of internal controls, adheres to the principles of independence, objectivity and impartiality, and fully performs the supervision functions of internal audit. In 2025, the company further strengthened the construction of internal control and risk management systems, carried out special audits on the company's important business modules and internal control implementation, and evaluated the company's internal management and business, thereby effectively reducing internal management risks and providing positive guarantees for the company's standardized operations and steady development.

High quality development

Innovation is the foundation of Antu Biotechnology. During the company's more than 20 years of development, the company has adhered to the innovative spirit of "pursuing excellence and perseverance" and continued to deepen its efforts in the field of in vitro diagnostics: continuously increasing investment in innovation, enriching product lines, and enhancing core competitiveness; through independent innovation, mastering core technologies and getting rid of "stuck necks"; absorbing and cultivating technical talents, improving the R&D system, and building technology platforms. In addition, Antu Biotechnology adheres to the service concept of "user first, creating value", adheres to user-centeredness, provides diversified services, and expands more space for high-quality development.

Antu Biotechnology 2025 Social Responsibility Report

Innovation leads enterprises to high-quality development

Antu Biotechnology has always regarded innovation capabilities as an important means to enhance the core competitiveness of enterprises, and led the high-quality development of enterprises with innovation. In 2025, R&D investment will be 768 million yuan, accounting for 18.16% of operating income, and the total number of R&D personnel will exceed 2,000.

Proportion of Antu Biotech’s R&D investment from 2023 to 2025 (unit: 100 million yuan)

R&D investment operating income

44.44 44.71

42.26

7.68

6.56 7.32

Accounting for 14.77% in 2023 and 16.37% in 2024 Accounting for 18.16% in 2025. As of December 31, 2025, the company has obtained 1,986 patents (including 54 international patents), of which domestic patent authorizations include 443 invention patents, 1,311 utility model patents, and 178 design patents; it has obtained 1,025 product registration (filing) certificates, and has obtained EU CE certification for 669 products. The company has undertaken 28 national projects, 22 provincial projects, and 30 city-level projects, completed 13 scientific and technological achievement appraisals (evaluations), and has fully participated in the formulation of 116 national/industry standards.

In terms of scientific research platform construction, the company has undertaken two industry chain main projects of the Ministry of Industry and Information Technology; the "Automated Clinical Test Laboratory Promotion and Application Project" led by the company ranked first in the IVD automated clinical laboratory category in the "2025 High-end Medical Equipment Promotion and Application Project" announced by the Ministry of Industry and Information Technology and other three ministries, demonstrating the company's strong strength in the field of high-end medical equipment.

In terms of R&D layout, with its Zhengzhou headquarters as the center, Antu Biotech has built technology platforms in different directions such as immunity, microbiology, biochemistry, molecules, coagulation, POCT, etc., and established R&D centers in Beijing, Shanghai, Suzhou, Shenzhen, North America and other places, making full use of local talents and technical advantages to enter the development of cutting-edge technologies and products in the field of in vitro diagnostics.

In 2025, the company was selected for the "Top 100 Enterprises in China's Pharmaceutical Industry" list for two consecutive years; it topped the "China IVD Enterprise R&D Strength List" in 2025; the fully automatic biochemical analysis AutoChemB2000 series won the German iF Design Award; the assembly line AutolasX-1 won the 25th China Patent Award for Appearance Design Excellence Award, etc. The acquisition of these honors is a high recognition of the company's strength by the country and the industry.

Antu Biotechnology 2025 Social Responsibility Report

Pursue sophisticated manufacturing and create high-quality products

· Assembly line solution · ·Immune solution ·

As the leading unit of the national key R&D program "Fully Automated High-Performance Laboratory Assembly Lines with 515 Registration (Filing) Certificates and Obtained System R&D" projects, Antu Biotech has obtained EU CE certification for 368 products in the laboratory assembly line field after more than ten years. Exploration of reagent products, with relatively deep technical accumulation, through the three-step strategy of the assembly line, it has realized laboratory assembly line products from scratch, from local brands to locally developed and manufactured thyroid function, eugenics and postnatal care, hypertension, etc.: In 2017, it was the first to launch a fully automatic magnetic levitation flow in medical laboratories in the Chinese market. In 2017, it was the first to launch a fully automatic magnetic levitation flow detection direction for medical laboratories. It is the first immunoassay line Autolas in my country. A-1 series; in 2019, it launched one of the largest number of fully automatic flow testing products for intensive medical laboratories, and it is also the domestic line Autolas B-1 series; in 2022, it launched a new independent research and development production line Autolas X-1 series, an enterprise line capable of providing comprehensive immune testing solutions. At present, Antu Bio's biological assembly line has more than 220 magnets. In terms of testing instruments, Antu Bio's particle chemiluminescence testing project and 125 biochemical testing projects have broken through the core raw material technology of reagent cores and launched the fully automatic chemiluminescence meter AutoLumo, achieving a high self-sufficiency rate, and the stability of reagents has reached the international advanced level. AutoLumo A2000 Plus, high-throughput chemical development

The photoimmunoassay analyzer AutoLumo A6000 is an Autolas

series, providing clinical services with efficient randomization, flexibility, and the introduction of AI testing clinical decision-making aids, artificial intelligence serum quality identification, and laboratory testing.

Such automated immunoassay solution.

Quality control and other functions continuously improve detection efficiency and contribute to the intelligence of medical laboratories.

Energy-based construction. In addition, the assembly line is equipped with the newly upgraded AutoLean® lean management

The overall solution helps laboratories implement lean improvement projects and promote high-quality laboratories

Quantitative development.

Autolas X-1 Series - - AutoLumo A6000 -

· Biochemical solutions · · Coagulation solutions · Possess 201 registration (filing) certificates, of which 124 products have been actively deployed in the field of coagulation testing, and have strategically cooperated with Hiken Medical to obtain EU CE certification. The reagents cover liver diseases, kidney diseases, and operations, and a coagulation detection platform has been built. Currently, the products cover 12 categories including high-throughput cardiovascular diseases, glucose metabolism diseases, and immune diseases. Coagulation series, coagulation assembly line, supporting (compatible) coagulation reagents, the company launched a new generation of fully automatic biochemical analyzer AutoChem to provide users with coagulation solutions for multi-scenario needs. B2000 and AutoChem B800 series are suitable for large and medium-sized medical laboratories.

Laboratories, outpatient and emergency laboratories provide more flexible and complete solutions

scheme.

AutoChem B2000 - - AutoCimo C6000 -

· Microbial Solutions ·

It has 168 registration (filing) certificates and has obtained EU CE certification for 88 products. Antu

Biology has launched a variety of automated instruments in the field of microbial testing, in conjunction with the "microbiological laboratory

"Management System" realizes the seamless connection of detection data of various microbial processes, and can provide

The laboratory provides a series of intelligent solutions for all aspects of vaccination, culture, identification, and drug sensitivity.

In the field of microbial mass spectrometry detection, the global cumulative sales of MALDI-TOF mass spectrometers have exceeded 1,000 units;

The new generation of microbial mass spectrometry detection system Autof T series has been certified and launched. It is the world’s smallest fully automated

Animal and microbial mass spectrometer, using AIEF and TAA technology, has excellent performance in ion flight at extremely short distances.

Still maintains high sensitivity and high resolution; innovatively adopts 18.5-inch full touch screen design, which feels better in the hand

Silky and smooth, opening a new era of intelligent and convenient operation; the matching database covers more than 1,000 attributes,

More than 5,200 pathogenic microorganisms, including Antu’s characteristic filamentous fungi, marine aquatic bacteria, etc., further

It has consolidated the ability of accurate detection and will surely become a milestone product in the field of bacterial identification.

Autof T Series -

Antu Biotechnology 2025 Social Responsibility Report

·Molecular detection solutions · · Accurate detection solutions ·

It has 37 registration (filing) certificates and obtained 49 European product certifications. In the field of mass spectrometry detection, Antu Biotech's fully automatic liquid chromatography tandem mass alliance CE certification. The fully automatic nucleic acid purification and spectrum detection system AutoChrom This system utilizes the high resolution of high-performance liquid phase and mass spectrometry detection laboratories to provide more convenient and efficient nucleic acid detection products. Antu has the characteristics of high sensitivity, high specificity, etc., and can carry out multi-index joint detection. Biology has launched more than ten respiratory pathogen nucleic acid detection reagents to construct detection. It can also be combined with a fully automatic sample pre-processing system to form a mass spectrometry flow to form a complete fully automatic respiratory pathogen nucleic acid detection solution. line is the gold standard for detection of small molecule metabolites.

In the future, it will also be used in infectious diseases, sexually transmitted diseases, eugenics and postnatal care, and personalized medicine.

Comprehensive layout in pharmaceutical, rapid nucleic acid and non-clinical fields to further enrich

Rich molecule detection product line.

AutoChrom X1/Automs TQ6000 IVD System -

In the field of gene sequencing, the company's wholly-owned subsidiary Sikun Biotechnology launched the AISPre 3200 fully automatic gene sequencing library preparation system, which supports nucleic acid extraction, library construction, and library pooling to be completed automatically; - AutoMolec 3000 -

Four sequencers, including Sikun2000, 1000, 500 and RapidGS480, are on the market for non-clinical systems and can complete a sequence in as little as 3.5 hours.

·POCT solution·

Sequencing is fast, accurate, flexible, and stable. Launched the AutoFlex series, which inherits from Antu Bio's mature and accurate magnetic particle luminescence platform for pathogen metagenomic sequencing mNGS and pathogen targeted sequencing tNGS. It is the only one in the industry equipped with two series of native and scalable LDT products, a total of 7 LDT products. In addition, the intelligent quality control network that assists in early cancer can easily realize quality control management in multiple fields such as in-hospital/regional diagnosis of POCT and non-clinical pathogen whole genome sequencing. The AutoFlex system is compatible with whole blood, plasma, and blood work.

A variety of sample types such as serum and urine, and now has 13 detection tests

agent. In addition, the company launched Mycoplasma pneumoniae, influenza A/B

Influenza, adenovirus and respiratory syncytial virus antigen colloidal gold products have been approved

Batch launch, including adenovirus and respiratory syncytial virus detection products

It is the first domestic reagent that can be used for consumer self-testing, filling the market

Blank.

Sikun 2000 -

·Quality control solutions · ·Core raw material development ·

Antu Biotech and its holding subsidiary Shanghai Biaoyuan have obtained 72 quality control products. In terms of the development of core raw materials, Antu Biotech focuses on the development of medical device registration certificates for core raw materials and has 90 national secondary reference material certificates. After more than ten years of painstaking research and development and technology accumulation, it has created a diagnostic antibody library covering clinical examination, biochemistry, immunity, microorganisms, molecules and other experiments. It targets tens of thousands of antigenic epitopes, and immunodiagnostic reagents for medical subspecialty. BiQAS quality management software platform has become a major supplier of domestic products with high antigen and antibody self-sufficiency rate, ensuring the stability of supply and EQA and IQC software, with laboratory users exceeding 1.7 safety.

Thousands of families.

· Construction of smart medical laboratories and close medical alliances·

While continuously enriching its product lines and improving medical laboratory automation, Antu Biotech is also working on the construction of smart medical laboratories and close medical alliances, and has successively launched laboratory information management systems (LIS), remote service systems, assembly line middleware, microbiology laboratory management systems, laboratory management systems based on ISO15189 accreditation and other medical information products, achieving seamless connection and data interoperability of various testing processes in medical laboratories.

Based on medical knowledge, testing big data and artificial intelligence technology, an "AI testing clinical auxiliary decision-making system" has been developed to continuously explore the value of testing data and assist clinical decision-making. Currently, more than 5,000 test items and more than 3,000 disease interpretations are supported in the IVD field.

Actively participate in the construction of compact urban medical groups, county medical community regional medical testing centers and smart laboratories, upgrade and launch smart construction plans for regional medical testing centers, and help high-quality development of hospitals.

Intelligent laboratory -

Jiang (cid:0) Heilin Jining (cid:0) City Beijing North Gujiang Inner City Tianjin Hexi Shanxia (cid:0) Ningshan Haiqing (cid:0) Xigan (cid:0) Nanhe (cid:0) Jianghai (cid:7658) Anzang West North Lake Jiang Zhechuan Si Xijiang South Lake Jian Fuzhou (cid:0) Taiwan Tainan Xiyun (cid:0) Guangguang Hong Kong Hong Kong Macau South China

Bvup.jMJT

Antu Biotechnology 2025 Social Responsibility Report

Diversified services create value

Antu Biotechnology takes "customers first, creates value" as its service concept, insists on being user-centered, and continuously improves service standards and capabilities. It has a service team with strong technical strength to provide professional, timely and thoughtful services to domestic and foreign customers. It is one of the companies with more technical service personnel in the industry.

In terms of laboratory quality control services, Antu biomass control markers cover the four major series of immune, biochemical, molecular and clinical inspection; the market share of laboratory quality evaluation products continues to increase; BiQAS software realizes the mutual recognition function of test results, and the software platform has served thousands of medical laboratories.

In terms of laboratory management services, Antu Biotechnology has established Antu Medical Research and Education Center, dedicated to the dissemination of professional knowledge and the cultivation of testing talents; launched AutoLean® lean management consulting services to provide all-round support for lean management of medical laboratories; created a Lab-OEC comprehensive management system for medical laboratories, popularized advanced management concepts in medical laboratories, and improved medical laboratory management efficiency and management capabilities.

In terms of overall laboratory services, Antu Biotech is based on customer needs and provides customers with integrated services such as intensive laboratory supply, site planning and design, and intelligent construction to assist the overall development of medical laboratories in my country.

Employee Responsibilities

"People-oriented and focusing on personal development" is one of Antu Biotech's values. The company adheres to the concept of "employing people based on their strengths" and has established a complete human resources management system. By creating a flexible and efficient recruitment mechanism, a systematic and comprehensive training system, a positive and reasonable incentive and promotion mechanism, and a scientific and complete salary and welfare system, we create a good working environment, create a harmonious humanistic environment, and provide a broad platform for employee development, allowing every Antu employee to pursue their own life value in career progress and achieve common development between employees and the company.

Antu Biotechnology 2025 Social Responsibility Report

Talent strategy

We use people’s strengths and strive to let everyone use their talents;

We focus on learning and training and create an open working environment;

We employ talents in an eclectic way so that young people who are down-to-earth, hard-working and smart can stand out;

We require our managers to be open-minded and take cultivating talents as their own responsibility;

We pay attention to social security and ensure that every employee has a pension;

We continue to work hard to ensure that our employees receive good compensation and protection;

We care for each other, empathize with and pay attention to the sadness and frustration, happiness and joy of our employees;

We wish and expect every employee who joins the Antu family to have a happy and rewarding Antu life.

· Employment philosophy ·

Talent and team are the core competitiveness of an enterprise, and Antu Biotech attaches great importance to the construction of a talent team. The company's first criterion for employing people is to employ the director's strengths. It adheres to the talent concept of "employing the director; people first, policy second", puts people first, is people-oriented, respects talents, values talents, fully utilizes and brings into play the advantages of each employee at work, stimulates their potential, integrates the strengths of different employees, and jointly achieves career progress and development. Through years of selection, employment, education, and retention, the company has built a complete talent echelon and created a team of high-quality professional talents in various fields such as R&D, manufacturing, marketing, service, and management.

· Staff Recruitment ·

Antu Biotech has established a scientific and complete employee recruitment process, formulated talent recruitment and training plans based on corporate development needs, and recruited and selected talents through campus recruitment, social recruitment, targeted recruitment and other methods to provide the company with sufficient talent reserves. The company is based in Zhengzhou, looking at the whole country, and employs talents in an eclectic way, especially the use of young technical talents, to inject more vitality into the company's sustainable development. At the same time, we will strengthen the recruitment of outstanding fresh graduates from key universities in a targeted manner, strengthen the recruitment and introduction of senior managers and experts in the field of R&D, and reserve talents for business development.

·Employee Profile·

Number of employees from 2023 to 2025: 6,000

5539 people 5757 people 5700 people 5000

As of the end of 2025, the company has 5,700 employees, including R&D

4000

2,005 people, accounting for 35.18%; bachelor degree or above

3000

4,150 people, accounting for 72.81%; 3,526 male employees and 2,000 female employees

There are 2,174 sexual employees. 1000

2023 2024 2025

Proportion of professional composition categories of employees in 2025 Proportion of employee age in 2025 Proportion of employee education level in 2025 Production personnel Financial personnel 30 years old and below 41 years old - 50 years old Master's degree and above College technical personnel Administrative staff 31-40 years old Over 50 years old Bachelor's degree Sales personnel below junior college

5% 1%

7% 9%

22% 22%

29%

22%

35%

61%

35% 51%

Antu Biotechnology 2025 Social Responsibility Report

career development

Antu Biotechnology attaches great importance to employees' learning and development needs and has established a complete training system. According to the different requirements of each position, we develop differentiated ability improvement training and establish a training management system that combines internal and external training to cover all employees in breadth and implement courses at all levels from new employees to old employees, from grassroots employees to senior managers in depth.

· Training system ·

program settings. Form two major training resource libraries of internal lecturers and external lecturers, and formulate training plans at all levels based on company development needs, job shortcoming improvement needs, necessary training needs and other information. Carry out various trainings such as talent development, comprehensive quality, and regular training to provide employees with a comprehensive learning platform. At the same time, we develop talent training plans for personnel in different positions, and cooperate with universities to entrust training to continuously improve the technical level of employees. The formulation of training plans, training completion status, training time, etc. are used as training performance evaluation indicators, striving to improve employee standards, strengthen experience transfer, promote company development, and comprehensively improve personal comprehensive capabilities while completing training work.

Continuous employee training

Based on the analysis at the strategic level, task level and employee level, combined with the company's development needs, job shortcomings improvement needs and other information, we provide employees with appropriate learning resources and content, and encourage employees to participate in various professional trainings; combined with the company's actual pain points, self-research and develop internal courses; develop talent training plans for different positions, and systematically select outstanding talents for further study; hire well-known domestic and foreign experts to hold special lectures, and carry out employee training and education.

Create a learning organization

The company's senior leaders actively participate in management and technical training, personally give lectures to mid-level cadres, use case analysis and various meetings to summarize experiences and lessons, and promote work improvement. Organize various departments to conduct learning and interactive exchanges at different levels and scopes to promote the sharing of advanced experience and the growth of employees. Continuously strengthen the collection and summary of knowledge and information within the company, establish an information and knowledge sharing system, and actively utilize external and internal communication channels to enable all employees to obtain and share knowledge and information in a timely manner, continuously improve their quality and capabilities, and achieve common development between employees and the company.

Create an employee continuing education platform

As a professional platform for internal employees to learn and grow, the Management Department of Antu Medical Research and Education Center takes "accurately disseminating practical management knowledge and cultivating management talents" as its teaching goal. It relies on the rich resources inside and outside the company to create an internal learning sharing circle and provide a continuous education platform for internal employees.

In 2025, for internal employees, we will continue to adopt a combined online and offline teaching model, enrich training forms, integrate internal and external teaching teams, and create Antu-exclusive training courses. Among them, a total of 52 training sessions were held throughout the year, such as the Launch Plan, the Concentration Plan, the Inheritance of Intelligence, and the Empowerment of Managers, with a total of 284 hours of training, and a total of 11,712 people trained; 75 new employee training sessions were held throughout the year, with a total of 1,242 people trained.

Overview of employee training in 2025

Visitors

hours

2025 General Training

Company level training

Department and team level training

external training

0 10000 20000 30000 40000 50000 60000

Antu Biotechnology 2025 Social Responsibility Report

Antu Biotech adheres to the corporate values of "people-oriented, focusing on personal development" and creates a smooth career development path.

·Development Channel·

Path, help employees formulate, implement and realize career development plans, continue to stimulate employees' potential and realize their self-worth.

Smooth career development path

Antu Biotechnology attaches great importance to the career development of its employees and designs multi-channel career development paths to create conditions for employees' development. The company's human resources department regularly communicates with employees to understand their development aspirations, and grasps the strengths and weaknesses of employees' career development through continuous work feedback, communication, meetings, etc. The company has established multiple levels of career development channels, special talents can be promoted across levels, strengthened the recruitment, performance, and training system for high-tech talents and compound talents, and established a smooth employee development path.

Complete talent development plan

The company has improved the internal competition system, set up scientific job grade standards, and formed a unique "dual channel" of career development - technical route and management route. Whether they are technical talents or management talents, they can find a ladder-type career development system that suits them. Relying on the management information platform "Antu OEC Performance Management System", we implement performance links such as "goal setting, implementation supervision, communication feedback, and incentives" to select talents, cultivate successor qualifications and abilities, form a talent echelon, improve sustainable operation capabilities, and achieve a win-win value for the company and talents.

occupational safety

Antu Biotech always regards safety as the lifeline of the company's survival and development, insists on unremitting efforts in safety production, establishes and improves a safety production responsibility system for all employees, and clarifies the safety responsibilities and obligations of personnel at all levels. The company has established a safety and environmental department, which is responsible for supervising and inspecting, guiding and coordinating the company's production safety, occupational health, environmental protection and other related work, and organizing regular assessments of relevant departments. By continuously improving the safety management system, standardizing safety behaviors, and cultivating safety culture, we create a safe and healthy working environment for employees.

· Safety management system construction · · Occupational health management ·

·Development Channel·

Based on the safety management system, the company has established and improved long-term safety production machines. The company adheres to the principle of prevention first and protecting the occupational health of workers. New employees arrive. On the basis of the original safety production standardization and dual prevention mechanism, the company's HR department will inform employees in detail about the occupational health hazards of the position before they start the job, regularly carry out the identification of safety laws and regulations, compare the latest revisions and safety protection measures, regularly identify the occupational disease hazard factors in the position, and update the relevant management systems, operating procedures and risk notifications, and hire a qualified third-party professional agency every year to identify and risk graded management and control of all job hazards involving occupational hazards, and carry out "four new" safety assessments. and the environment are tested, and the test results are all in line with national occupational health standards; the company is incorporated into the online system of dual prevention mechanisms, and hidden dangers are regularly arranged on site. The department strictly implements occupational disease physical examinations, increases security inspections for positions with occupational disease hazards, and does a good job in both offline and online dual management. Full protective measures are taken to ensure the physical and mental health of employees.

The company carries out the "Law of the People's Republic of China on the Prevention and Control of Occupational Diseases" publicity week and health lectures every year, and invites occupational health experts to provide relevant knowledge lectures and on-site Q&A on positions involving occupational disease hazards to enhance employees' awareness of self-protection. At the same time, the company organizes relevant employees to undergo occupational disease physical examinations every year.

Pay attention to various indicators of physical examination results to promote the physical and mental health of workers.

Antu Biotechnology 2025 Social Responsibility Report

· Emergency Management · · Safety Training and Publicity ·

Relying on the company's emergency response mechanism of "early warning - prediction - plan - rehearsal", safety culture, as an important part of corporate culture construction, plays an important role in organizing mini fire stations and emergency rescue teams to carry out physical fitness, skills and emergency safety management during the company's safety period. Safety culture is not something we are born with. It requires various professional trainings and strengthens the comprehensive quality and emergency response of emergency rescue personnel. It is the result of employees being publicized, trained and influenced for a long time in an enterprise. disposal capabilities. The company pays close attention to extreme weather conditions (such as high temperatures in summer, violent rainy weather, extremely cold weather in winter, etc.), promptly releases early warning information, and notifies all employees. The training is to increase employees' job safety knowledge, improve safety literacy, and enrich job functional departments to make emergency preparations for personnel and materials. Safety experience is an important way to shape job safety, especially the three-level safety education for new employees must be implemented, trained and informed in place.

According to the company’s annual drill plan, fire evacuation, mechanical

Injuries, limited space, pressure vessels, flood prevention drills, trapped people in elevators, electric shocks. Antu Biotechnology has always adhered to the safety concept of "safety first, prevention first, strict prevention and control, 22 drills of various types such as accidents, forklift accidents, chemical poisoning, etc., with a total of participants participating". Through accumulated publicity and training, 2,558 people were mobilized; for newly opened areas, it is required to use one and drill one to ensure that From the most basic "I want safety" to the deeper "I want safety", the security personnel are familiar with the site layout, familiar with fire-fighting rescue and evacuation and escape emergencies, and proactively identify and maintain safety.

Disposal skills.

In June and December 2025, the company carried out a series of safety activities with the theme of "Everyone pays attention to safety, everyone knows emergency response - look for safety hazards around you", such as everyone coming to "find faults", learning safety hazard manuals, watching safety warning films, firefighting skills competitions, hidden hazards shooting, safety guessing, safety star evaluation, etc. Employees from all departments were enthusiastic and actively participated. A total of more than 3,800 people participated in the two activities. In 2025, a total of 52 safety trainings of various types will be implemented, with 4,656 trainees; the coverage rate of new employee safety training and special training on job operations will be 100%; the special training includes training on special equipment such as forklifts, pressure vessels, and elevators, hazardous waste management, occupational disease prevention and control, fire safety, hazardous chemical safety, biosafety, etc.

Antu Biotechnology has always adhered to the goal of zero safety accidents. By carrying out continuous safety inspections, safety training, emergency drills, risk identification and other work, the company's safety work will be carried out smoothly and orderly in 2025, with no general or above safety production accidents occurring, and the goal of zero safety accidents will be achieved.

· Biosafety Management ·

As a professional in vitro diagnostics company, Antu Biotech always places biosafety as its top priority and conducts training and publicity to strengthen safety awareness.

Want location. The company strictly abides by national regulations and corporate internal control requirements, and systematically

The company has established a biosafety management system covering the entire chain of R&D, production and quality control by building a three-dimensional educational model that combines education and entertainment, and carried out simulation exercises.

diversified activities such as training and fun safety activities to enhance the absorption of safety knowledge. Through standardized process design and strict risk management and control mechanisms, full flow can be achieved

Gravity, further strengthen employees' safety awareness, provide standardized management for the biosafety management system, and effectively ensure the sustainable operation of the enterprise and the health and safety of employees.

Lay a solid foundation for efficient operation and protect the health of employees.

Collaborative development of dimensional goals.

Biosafety practice results

The company actively coordinates and integrates existing laboratory resources, and has built 14 BSL-2 laboratories with high standards, and has fully integrated them into the unified management of the national pathogenic microbiology laboratory management service platform to achieve standardization of laboratory construction, standardization of operation, and informatization of management. The laboratory strictly abides by biosafety laws, regulations and technical specifications, and carries out experimental activities related to various pathogenic microorganisms in a scientific and orderly manner in accordance with laws and regulations. Biosafety assurance capabilities, risk prevention and control levels and scientific research support efficiency have been significantly improved, building a solid and reliable biosafety defense line for the company's scientific research innovation and high-quality development.

Establish biosafety management systems and systems

File Category File Location

Level 1: 1 copy of Laboratory Biosafety Manual

Second level: 29 program documents

The third level: 127 three-level documents

The company strictly abides by the "Biosafety Law of the People's Republic of China" and establishes a biosafety

Safety management system, covering personnel, environment, equipment, bacteria (virus) species, etc.

Develop emergency plans and strengthen emergency drills. By signing the Biosafety Responsibility

The book clearly clarifies the standardized responsibilities of employees in experimental operations to ensure that the experiments are safe and reliable.

control. The company incorporates biosafety knowledge into its employee training system to improve the cooperation of all employees.

Awareness of rules.

Antu Biotechnology 2025 Social Responsibility Report

Employee protection

·Salary and welfare system ·

In order to protect the rights and interests of employees and ensure their interests such as wages, working hours and vacations, labor safety, social insurance and welfare, Antu Biotech strictly follows the requirements of the Labor Contract Law of the People's Republic of China and has established a scientific, reasonable and competitive salary mechanism, appropriate incentive policies and a complete welfare security system.

Salary Benefits

The company has established a complete salary and welfare system and performance appraisal system in terms of salary.

The system is a floating salary system that combines fixed salary with performance rewards. company

The total remuneration is determined based on the completion of the company's main operating indicators. in total salary

within the quota, taking into account industry salary levels and internal fairness and reasonableness within the company

gender, and develop competitive fixed salary standards; the company has implemented OEC for many years

Performance management model, established a reward and punishment system, based on the company's various centers or

Develop performance incentive plans for relevant personnel based on the department's key performance indicators, so that

Compensation is combined with performance appraisal results. The company also sets up a position-specific allowance machine

system and improve the company’s welfare system. In order to keep the company's development vitality, employees are encouraged to

Workers actively provide suggestions on the company’s performance development, technological innovation, management optimization, etc.

Offer advice. With the development of the company, on the basis of ensuring the basic income level of employees,

On the other hand, different salary structures are established according to the nature of the position. For functional positions, Antu Biotech attaches great importance to the legitimate rights and interests of employees and follows the "Labor of the People's Republic of China focuses on fixed wages to ensure personnel stability; performance positions focus more on floating laws", the Trade Union Law of the People's Republic of China and other relevant laws and regulations, and formulates the proportion of salary to ensure the realization of company goals, so as to effectively motivate employees, and the "Employee Welfare Management System". The company pays five insurances and one fund for employees, provides employees with full motivation and potential, and strives to create attractive statutory paid holidays. It also provides employees with labor insurance, holiday benefits, clothing, food, and talent, an environment that retains talents and encourages talents to stand out, and attracts more welfare guarantees such as quality housing and transportation. The perfect welfare system, diversified talents and enterprises grow together. Welfare measures not only enhance employees' sense of happiness and belonging, but also enhance corporate cohesion and centripetal force.

free

Customized work meals for employees

work clothes dormitory

Employees Commuter Travel Employee Benefits Shuttle Bus

festival health

Welfare Daily Physical Examination

labor insurance

· Targeted assistance ·

In order to further improve the welfare of employees, Antu Bio has successively established projects within the company such as the "Antu Bio Mutual Aid Fund", "Antu Outstanding Sons and Daughters Scholarship", and "Antu Bio Needy Fund" to provide targeted assistance to employees in need based on improving employees' family lives. In 2025, the company will continue to provide targeted assistance to employees whose families are in difficulty.

The company has set up the "Antu Biological Mutual Aid Fund" internally to provide financial support to employee families whose lives are in trouble due to illness and accidents; in order to encourage the children of employees to study diligently and serve the country, the company has established the "Antu Outstanding Children Scholarship" internally to provide financial support to the children of employees with outstanding achievements. A one-time reward of RMB 5,000; in order to better implement care for employees and further improve the welfare security system, the company has set up the "Antu Biology Poverty Assistance Fund" to provide assistance to employees whose families are unable to improve due to illness, accidents, or long-term difficulties in raising children or supporting the elderly due to family members.

Antu Biotechnology 2025 Social Responsibility Report

· Human environment ·

The company creates a harmonious humanistic environment through measures such as carrying out cultural and recreational activities and continuously improving the working environment and living facilities. In 2025, the company will regularly carry out cultural and entertainment activities such as employee birthday parties, holiday garden parties, and football matches to enrich the spiritual and cultural life of employees; hold various forms of symposiums such as new employee symposiums and old employee symposiums to build a communication platform; and provide employees with more complete living facilities such as dormitories, shuttle buses, and restaurants to facilitate employees' work and life. The company strives to create a warm and harmonious working and living environment so that every employee can feel the warmth of the Antu family, where they can learn from each other, trust each other, work together, and develop together.

Green development

Antu Biotech insists on building a green and environmentally friendly enterprise, adheres to the concept of "sustainable development", and regards green development as a key part of the company's high-quality development. The company establishes and improves the environmental protection and development system, advocates low-carbon and energy-saving work and life, spreads green culture, cultivates employees' awareness of environmental responsibility, and relies on advanced technical means to build pollutant treatment facilities to reduce the impact of pollutants on the environment.

Antu Biotechnology 2025 Social Responsibility Report

green management

Antu Biotechnology has always adhered to the development concept of a green factory, based on the premise of protecting the ecological environment and promoting sustainable development, formulating ecological environment-related systems, building an environmental quality system, popularizing ecological and environmental protection knowledge, enhancing employees' ecological and environmental protection awareness, and continuously optimizing emergency drills and training for environmental emergencies. Successfully applied for Zhengzhou Green Factory and Henan Province Green Factory in 2025.

Combined with the development and changes of the company, we will continuously improve and optimize the existing list of environmental factors, update the identification and compliance list every quarter, and establish an environmental system.

Improve the environmental management system and make the environmental management system more mature and complete. Regularly conduct internal audits of the environmental system to ensure compliance with the system

Compliance items will be rectified and verified.

The company has always taken it as its mission to popularize ecological and environmental protection knowledge and enhance employees' ecological protection awareness. In 2025, environmental training and

Emergency drills for hazardous waste management, environmental factor identification and management, environmental management system, environmental protection and safety, occupational health laws and regulations, etc.

Company-level training, with a total of 3,469 people trained.

Plan and implement simultaneously. In order to improve the emergency response capabilities of employees, combined with the emergency plan for environmental emergencies, three emergency drills for sewage treatment stations, hazardous waste leakage emergency drills, and environmental emergency drills in the factory area were organized in 2025.

Green buildings are the sharing of interests between man and nature, present and future, and are a construction method to ensure the sustainable development of Kese. The company gives priority to environmentally friendly building materials during factory construction

building materials, reduce the use of decorative components, rationally layout the building; optimize the layout

Build water, water supply, and power supply systems, and actively implement energy-saving construction.

green

Green management starts from scratch. The company installs an environmentally friendly access control system and strictly manages the factory area.

color

Vehicles entering the factory. Vehicles with high pollutant emissions are prohibited from entering the factory area. Forklifts within the factory area are

thing

Use electric forklifts; at the same time, strengthen the management of cooperative logistics providers and require cooperative use

flow

Under the condition that the vehicles meet the environmental protection control requirements, they will gradually improve the level of National VI and new energy vehicles.

Vehicle transportation share.

Green management starts with details. In 2025, the company will continue to implement the concept of green and low-carbon, actively promote paperless office, add more than 150 online approval processes, and run a total of 550 online processes; use energy-saving lighting fixtures, and use energy-saving devices in the office area

Public tools; require employees to leave switchgear and encourage employees to take public transportation when going out.

Energy saving and low carbon start from the whole process. In the equipment procurement process, energy efficiency needs are increased,

Festival

Give priority to the use of high-energy-efficiency equipment; in terms of raw and auxiliary material selection, give priority to the use of environmentally friendly materials

Energy and materials; in the production process, strengthen the maintenance and management of production equipment to reduce the risk of equipment aging.

Low energy consumption or high energy consumption caused by failure, continuously optimize the production process, and improve the quality of raw materials and auxiliary materials

Utilization rate; in the waste treatment process, waste is classified and disposed of.

Carbon

Resource utilization. Continuously optimize and adjust the operating parameters of energy-consuming equipment to reduce equipment energy

Consumption, successfully passed the energy management system certification in 2025, and obtained the energy management system

Certification certificate.

Antu Biotechnology 2025 Social Responsibility Report

green

Pollutant management

color

Pollution control is the obligation of enterprises, and it is also the responsibility of enterprises. Antu Biotechnology always adheres to the synchronization of development and environmental protection, and production and construction

At the same time as pollution control, we should actively build, improve and upgrade pollutant treatment facilities, and do our best to reduce the impact of pollutants on the environment.

influence.

The company continues to optimize the wastewater discharge management process and improve the wastewater discharge management system. The drainage in the factory area adopts rainwater and sewage diversion, and sewage is discharged

green

Collect, process and discharge water quality, install a sewage online monitoring system, and formulate routine monitoring plans to manage sewage regularly.

Se line water quality monitoring; at the same time, strengthen the management of operators and maintenance providers of online sewage monitoring equipment, formulate assessment indicators, conduct regular spot checks on daily maintenance items, and ensure that the online sewage monitoring equipment operates in compliance; sewage discharge will meet the standard in 2025, and no excessive discharge will occur.

flow

The oil fume in the factory canteen reaches the standard after being treated by the oil fume purifier, and online monitoring equipment is installed; the R&D exhaust gas adopts two exhaust gas management

green

After grade activated carbon adsorption treatment, the emissions meet the standard. The steam generator adopts WCB premixed combustion technology; the "Restaurant Color" is formulated and improved.

"Oil Fume Purification System Management System", "Spray Tower Standard Operation, Cleaning and Maintenance Procedures", etc., according to the system and procedures

Daily maintenance of waste gas treatment equipment is carried out according to regulations; regular monitoring is entrusted to a third party. In 2025, the waste gas emission standard rate will be 100%, and no pollution accidents will occur.

Festival

can

low

Carbon

According to the "Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste", the company has set up temporary storage rooms in the factory area to store solid waste.

Classified collection, storage, utilization and disposal of physical waste. Strengthen the recycling of solid waste and manage non-recyclable waste

Entrust qualified companies for disposal; at the same time, strengthen daily supervision of solid waste classification, conduct spot checks on the classification and storage of solid waste, and ensure the legal and compliant disposal of solid waste.

For noise control, the company starts from every detail. From the early stage of factory design, the noise source equipment is arranged at a distance away from ambient noise.

Live far away from the community; purchase low-noise equipment, strictly follow the specifications when installing the equipment, and strengthen the maintenance and management of the equipment.

Maintain and eliminate outdated equipment in a timely manner; entrust a third party to monitor the noise at the factory boundary. Canteen exhaust gas

R&D waste gas

Developing self-monitoring plans in accordance with the law and implementing the self-monitoring system are safety locks for enterprises to ensure that pollutants are discharged in compliance with standards. Company self-monitoring

Formulate an annual monitoring plan for wastewater, waste gas, and noise, and regularly entrust a third party to conduct annual monitoring. There will be no exceedances throughout 2025.

Antu Biotechnology 2025 Social Responsibility Report

Compliance and environmental investment

Legality and compliance are powerful guarantees for the stability and long-term development of an enterprise. The company's new projects proactively and proactively implement the Three Simultaneities of Environmental Protection, carry out environmental assessment, environmental acceptance acceptance and other environmental protection procedures, and carry out the construction of various environmental protection facilities. In 2025, the company invested 10.768 million yuan in environmental protection; in 2025, in accordance with the "Management Measures for the Legal Disclosure of Enterprise Environmental Information", environmental information was disclosed in accordance with the law; there were no excessive emissions and environmental pollution incidents throughout the year.

Detection value

Test Test Emission Test Item Indicator Standard Result 2023 2024 2025

COD 80mg/L 31.75 22 36.3 Qualified wastewater

Ammonia nitrogen 10mg/L 1.251 0.771 0.482 Qualified food

Tang oil fume 1.0 mg/m³ 0.45 0.65 0.1 Qualified waste

angry

non-methane

10mg/m³ 2.85 1.82 1.30 Qualified total hydrocarbons

Hydrogen chloride 100mg/m³ 6.96 Not detected 0.21 Qualified

send

Waste methanol 20mg/m³ 5.61 0.133 0.104 Qualified gas

exhaust gas

non-methane

60mg/m³ 2.45 1.468 1.207 Qualified total hydrocarbons

Smoke 10 1.3 1.20 2.90 Passed

Sulfur dioxide 30 Not detected Not detected Not detected Passed

Nitrogen oxides 50 15.7 20.1 19.4 Passed

Daytime 60dB 55 55 55 Qualified noise

Night 50dB 45 45 45 Passed

Antu Biotechnology will always adhere to the development concept of green factories, based on the premise of protecting the ecological environment and sustainable development, continue to improve production processes, reduce pollution emissions, strictly enforce environmental management systems, conscientiously and strictly fulfill corporate environmental responsibilities, and contribute to the sustainable development of the environment.

Social Responsibility

Antu Biotechnology advocates the spirit of hard work within the company, donates generously to society, and gives with all its heart. It is a warm-hearted company with a strong sense of social responsibility. Over the years, while achieving its own good development, Antu Biotech has actively participated in public welfare and given back to the society: from establishing the "Antu Forward Scholarship" and "Antu Forward Veterans Solace Fund" to philanthropic investment in the construction of the country's first laboratory medicine museum; from actively supporting grassroots hospitals in the province to continuing to pay attention to groups in need, the company has always fulfilled its responsibilities and responsibilities with practical actions.

Antu Biotechnology 2025 Social Responsibility Report

In 2025, Antu Biotechnology will continue to promote the external public welfare projects "Antu Advance Scholarship" and "Antu Advance Veterans Solace Fund".

Help cultivate inspection personnel, support the military and provide preferential care,

Establishing the "Antu Advance Scholarship" and the "Antu Advance Veterans Solace Fund" to support outstanding college students from poor families to complete their studies and cultivate talents for the country are the public welfare work that Antu Biotechnology has been doing during the Anti-Japanese War, the Liberation War, and the Anti-U.S. War. In 2007, Antu Biological first aided Korea and other wars, and the people of Nanzhao made great contributions to the cause of the country and the nation. The "Antu Advance Scholarship" was established at Zhengzhou University, aiming to make great sacrifices for colleges and universities. In 2017, Antu Biotechnology established the "Antu Biotech to provide financial aid to outstanding veterans with difficulties in their careers so that they can successfully complete their studies and repay the National Soldier Solace Fund" in Nanzhao County, providing financial support to more than a hundred retired veterans and disabled veterans in Nanzhao County. Over the past 17 years, the Antu Advance Scholarship has been set up in 34 colleges and universities inside and outside the province, providing each person with a cash subsidy of 5,000 yuan per year to help them spend their old age peacefully. At present, it has rewarded and funded more than 2,500 outstanding students with financial difficulties, and has supported some for nine consecutive years, supporting more than 1,000 veterans in total, and donated funds and teaching equipment to university laboratories. More than 5 million yuan. In 2025, a total of 131 veterans were supported and funds donated

674,500 yuan.

In 2025, Antu Advance Scholarship will be established in six new colleges and universities; a total of annual awards

It has supported more than 360 students with excellent academic performance and donated 1.0741 million yuan in scholarships. Not yet

In the future, the Antu Advance Scholarship will be established in more colleges and universities across the country, benefiting more students.

A student with excellent academic performance.

Future Outlook

Become a provider of medical laboratory products and services with brand influence; repay employees, investors and society.

Antu Biotechnology 2025 Social Responsibility Report

Innovation empowers, improves quality and efficiency, deepens industry and builds health together

In 2025, when the Healthy China strategy is further advanced, the in vitro diagnostic industry will usher in a key turning point in structural adjustment and high-quality development. Policy guidance, technological innovation and market adjustment will continue to integrate, and the industry is accelerating its transformation from "quantitative expansion" to "quality upgrading". As an important member of the in vitro diagnostic industry, Antu Biotech is based on the changes in the industry, continues the core strategy of innovation-driven, continues to make efforts in technological breakthroughs, product iterations, industrial upgrades and social responsibility practices, promotes high-quality development of the enterprise with hard work, and injects strong momentum into the development of the in vitro diagnostic industry.

In 2025, in vitro diagnostic technology will iteratively accelerate, and precision, intelligence, and scenario-based development will become the core development directions. Antu Biotech closely follows the pulse of industry development, continues to increase investment in R&D, and builds a technology "moat" with high investment. The proportion of annual R&D investment in operating income increased to 18.16%, with R&D investment reaching 768 million yuan. New products achieved fruitful results throughout the year. Three gene sequencers developed by wholly-owned subsidiary Sikun Biotechnology obtained the medical device registration certificate from the State Food and Drug Administration, officially entering the clinical testing market; a series of liquid chromatography tandem mass spectrometry products were launched to fill the company's technical gaps; new products such as the microbial mass spectrometry detection system Autof T series and the fully automatic chemiluminescence immunoanalyzer AutoLumo S900 were successively certified and launched, further enriching the matrix of accurate detection products.

In terms of smart application of medical laboratories, the company optimizes and upgrades the overall smart laboratory solution based on the original laboratory information management system, AI test clinical auxiliary decision-making system, and combined with industry AI technology development trends, and deeply participates in the construction of compact urban medical groups and county medical community regional medical testing centers to help medical institutions achieve standardization of testing processes, data interoperability, and intelligent analysis.

In terms of innovation in production methods and governance models, the company continues to deepen the construction of green factories, optimize automated and intelligent production processes, and achieve green, efficient, and sustainable production; improve modern corporate governance mechanisms with clear rights and responsibilities and mutual checks and balances, strengthen compliance management and risk management, ensure that corporate operations are legal, compliant, efficient and orderly, and lay a solid foundation for the company's long-term development.

Antu Biotech always adheres to the concept of serving the country through industry and rejuvenating the country through industry, and deeply binds corporate development with social contribution. We pay taxes with integrity in accordance with the law and contribute to the national economic construction and the development of the biopharmaceutical industry; we continue to create high-quality jobs and actively recruit university graduates and social workers; we improve the employee career development system, carry out various skills training, create a humane working environment, and help employees realize their personal value and corporate development. In terms of public welfare undertakings, the company has established projects such as the "Antu Advance Scholarship" and "Antu Advance Veterans Solace Fund" to support college students and care for veterans in many provinces across the country. It also participates in medical scientific research public welfare, grassroots medical assistance and other projects to give back to the society with practical actions and convey the company's warmth.

Standing at the new starting point of the "15th Five-Year Plan", Antu Biotech has always adhered to the beautiful vision of "becoming a provider of medical laboratory products and services with brand influence, repaying employees, investors, and society." Based on the core track of in vitro diagnostics, Antu Biotech continues to promote technological leaps, industrial upgrades, and international layout. In the future, Antu Biotech will continue to take innovation as its core driving force, focus on cutting-edge technologies such as nucleic acid sequencing and mass spectrometry, promote the company's comprehensive upgrade from traditional diagnosis to precision diagnosis, return shareholders and society with better performance, forge an influential and outstanding in vitro diagnostic company in the industry, and write a more brilliant new chapter for human health.

Zhengzhou Autobio Bioengineering Co., Ltd. www.autobio.com.cn